BiotechTube

Pirtobrutinib + Mosunetuzumab

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Grade 1 Follicular Lymphoma

Conditions

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma

Trial Timeline

Nov 17, 2025 → Jul 31, 2031

NCT ID
NCT06948786

About Pirtobrutinib + Mosunetuzumab

Pirtobrutinib + Mosunetuzumab is a phase 2 stage product being developed by Eli Lilly for Grade 1 Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06948786. Target conditions include Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma.

What happened to similar drugs?

0 of 7 similar drugs in Grade 1 Follicular Lymphoma were approved

Approved (0) Terminated (1) Active (6)
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3
🔄rituximabBiogenPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
🔄Remestemcel-LMesoblastPhase 3
🔄remestemcel-LMesoblastPhase 3
🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06948786Phase 2Recruiting

Competing Products

20 competing products in Grade 1 Follicular Lymphoma

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
azenosertibZentalis PharmaceuticalsPhase 2
32
Sepantronium BromideCothera BiosciencePhase 2
29
DS-1001bDaiichi SankyoPhase 2
39
Rabeprazole SodiumEisaiPre-clinical
26
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
Abemaciclib + LetrozoleEli LillyPhase 2
42
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
DSP-0390Sumitomo PharmaPhase 1
33
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
39
Mirvetuximab SoravtansineAbbViePhase 2
42
Acalabrutinib + ObinutuzumabAstraZenecaPhase 2
42
Olaparib Pill + AZD6738AstraZenecaPhase 2
35
PembrolizumabMerckPhase 2
42
Efineptakin alfa + PembrolizumabMerckPhase 2
42
PembrolizumabMerckPhase 2
39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + DocetaxelMerckPhase 2
35
CilengitideMerckPhase 2
31
AvelumabMerckPhase 2
35
Human Papillomavirus vaccineMerckPhase 2
35